We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+3.48%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$942M
AUM Growth
+$47.5M
Cap. Flow
+$57.7M
Cap. Flow %
6.13%
Top 10 Hldgs %
36.92%
Holding
174
New
107
Increased
33
Reduced
23
Closed
6

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$22.8M
2
FOLD
Amicus Therapeutics
FOLD
+$16.4M
3
COLL icon
Collegium Pharmaceutical
COLL
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.7M
5
AERI
Aerie Pharmaceuticals
AERI
+$10.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$24.4M
2
MOH icon
Molina Healthcare
MOH
+$17.5M
3
EXAS
Exact Sciences
EXAS
+$14.2M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$13.9M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 84.63%
2 Industrials 0.89%
3 Technology 0.84%
4 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
151
Spyre Therapeutics
SYRE
$8.5B
$124K 0.01%
+518
New +$121K
PRTK
152
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$124K 0.01%
+12,739
New +$128K
AVEO
153
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$119K 0.01%
+3,600
New +$92.5K
PGNX
154
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$113K 0.01%
+18,002
New +$138K
CDTX
155
DELISTED
Cidara Therapeutics
CDTX
$112K 0.01%
+1,272
New +$112K
TTPH
156
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$110K 0.01%
+1,991
New +$127K
CRVS icon
157
Corvus Pharmaceuticals
CRVS
$1.1B
$108K 0.01%
+12,594
New +$126K
NBRV
158
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$103K 0.01%
+153
New +$108K
PLX icon
159
Protalix BioTherapeutics
PLX
$183M
$72K 0.01%
+9,967
New +$50K
CTIC
160
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$70K 0.01%
+32,241
New +$79.8K
AVDL
161
DELISTED
Avadel Pharmaceuticals
AVDL
$67K 0.01%
+15,218
New +$82.2K
HSTO
162
DELISTED
Histogen Inc. Common Stock
HSTO
$60K 0.01%
+52
New +$47.9K
SLNO
163
DELISTED
Soleno Therapeutics
SLNO
$47K 0.01%
+1,439
New +$52.3K
GNCA
164
DELISTED
Genocea Biosciences, Inc.
GNCA
$26K ﹤0.01%
+4,117
New +$21.7K
VIRX
165
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$24K ﹤0.01%
+343
New +$26K
AGRX
166
DELISTED
Agile Therapeutics
AGRX
$16K ﹤0.01%
+23
New +$16.8K
ANAB icon
167
AnaptysBio
ANAB
$1.54B
– –
-34,100
Closed -$2.42M
EW icon
168
Edwards Lifesciences
EW
$49.4B
– –
-122,580
Closed -$5.95M
MOH icon
169
Molina Healthcare
MOH
$10.4B
– –
-178,870
Closed -$17.5M
RCKT icon
170
Rocket Pharmaceuticals
RCKT
$343M
– –
-237,158
Closed -$4.66M
NVRO
171
DELISTED
NEVRO CORP.
NVRO
– –
-84,000
Closed -$6.71M
PRAH
172
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-148,560
Closed -$13.9M
3 4 5 6
7

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sectoral Asset Management held 174 positions worth $942M, up 5.3% from $894M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sectoral Asset Management deployed $57.7M of net new capital in Q3 2018, opening 107 new positions and adding to 33 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $24.4M trimmed.

  • Sectoral Asset Management's largest Q3 2018 buy was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
  • Sectoral Asset Management added most to Celgene Corp in Q3 2018, an estimated $22.8M increase.
  • Sectoral Asset Management's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $24.4M.
  • Sectoral Asset Management fully exited Molina Healthcare in Q3 2018, selling an estimated $17.5M.
  • Sectoral Asset Management's ten largest holdings make up 37% of its $942M portfolio in Q3 2018.
  • Sectoral Asset Management opened 107 new positions and closed 6 in Q3 2018.
  • Sectoral Asset Management's portfolio value rose 5.3% quarter-over-quarter to $942M.

Based on Sectoral Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.